Onivyde (nanoliposomal irinotecan) / Ipsen, Servier, Yakult Honsha, Takeda, PharmaEngine 
Welcome,         Profile    Billing    Logout  

88 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
ChiCTR2400085193: To explore the efficacy and safety of bevacizumab combined with temozolomide and nanoliposomal irinotecan in patients with recurrent high-grade glioma

Recruiting
4
41
 
bevacizumab 5mg/kg ivgtt d1 temozolomide 100mg/m2 po d1-7nanoliposomal irinotecan 50mg/m2 ivgtt d1
Shandong Cancer Hospital Affiliated of Shandong First Medical University; Shandong Cancer Hospital Affiliated of Shandong First Medical University, self-financing
recurrent high-grade glioma
 
 
RESILIENT, NCT03088813 / 2017-004261-26: Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer

Completed
3
491
Europe, US, RoW
Irinotecan liposome injection, ONIVYDE®, Topotecan
Ipsen
Small Cell Lung Cancer
02/22
07/23
PREDICT, NCT03468335 / 2016-005147-17: 2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy

Active, not recruiting
3
270
Europe
Irinotecan Liposomal Injection [Onivyde], Nal-IRI
AIO-Studien-gGmbH, Crolll Gmbh, Servier Deutschland GmbH
Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
05/22
05/23
NAPOLI-3, NCT04083235 / 2018-003585-14: A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

Active, not recruiting
3
770
Europe, Canada, US, RoW
Irinotecan Liposomal Injection, Onivyde®, Nal-IRI, Oxaliplatin, Eloxatin®, 5Fluorouracil, Adrucil®, flurouracil, 5-FU, Leucovorin, Folinic Acid, Nab-paclitaxel, Abraxane®, Gemcitabine, Gemzar®
Ipsen
Metastatic Adenocarcinoma of the Pancreas
07/22
12/24
NCT06501664: Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC

Not yet recruiting
3
360
NA
liposomal irinotecan, Nal-IRI, 5-FU, Fluorouracil, LV, Calcium folinate, Irinotecan, IRI
Rui-hua Xu, MD, PhD
Esophageal Cancer
11/26
11/27
2017-000345-46: Study with anti cancer drugs in patients with resectable parcreatic cancer ¿nITRo trial" Studio con farmaci anti tumorali in pazienti con tumore del pancreas resecabile ¿studio nITRo¿

Not yet recruiting
2
67
Europe
oxaliplatino, 5-fluorouracile, lederfolin, Solution for infusion, Powder for solution for infusion, ONIVYDE, OXALIPLATINO ACCORD - 5 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 40 ML, FLUOROURACILE TEVA - 5 G/100 ML SOLUZIONE PER INFUSIONE 1 FLACONCINO DA 100 ML, LEDERFOLIN - 100 MG POLVERE PER SOLUZIONE PER INFUSIONE 1 FLACONCINO
CENTRO RICERCHE CLINICHE DI VERONA, Baxalta GmbH
Resectable pancreatic cancer Tumore pancreatico resecabile, Resectable pancreatic cancer tumore del pancreas resecabile, Diseases [C] - Cancer [C04]
 
 
2017-002453-11: NET-02: Second line therapy for patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma

Not yet recruiting
2
102
Europe
Liposomal irinotecan (Onivyde), 5-Fluorouracil, Docetaxel, MM-398, Concentrate for solution for infusion, Solution for injection, Liposomal irinotecan (Onivyde), 5-Fluorouracil, Docetaxel
The Christie NHS Foundation Trust
Poorly differentiated extra-pulmonary neuroendocrine carcinoma, Poorly differentiated (faster growing) neuroendocrine carcinoma that started in the gastrointestinal tract and has spread, Diseases [C] - Cancer [C04]
 
 
2017-003496-54: A multicenter randomized phase II study to determine the optimal first-line chemotherapy regimen in patients with metastatic pancreatic cancer (FOOTPATH) Eine randomisierte Multicenterstudie der Phase II zur Ermittlung des optimalen Chemotherapie-Regimes in der Erstlinientherapie von Patienten mit einem metastasierten Pankreaskarzinom

Not yet recruiting
2
270
Europe
5-Fluorouracil, Folinic Acid, Oxaliplatin, Gemcitabine, Nab-Paclitaxel, Concentrate for solution for infusion, Infusion, Onivyde
University Hospital, LMU Munich (Germany), Shire International
Histologically (not cytologically) confirmed diagnosis of metastatic pancreatic ductal adenocarcinoma (PDAC) [Stage IV according to UICC TNM edition 8 of 201622: each T, each N, M1] Histologisch (nicht zytologisch) bestätigte Diagnose eines metastasierten duktalen Adenokarzinoms des Pankreas (PDAC) [Stadium IV der UICC TNM Edition 8 von 2016 : jedes T, jedes N, M1], Metastatic pancreatic adenocarcinoma Metastasiertes Adenokarzinom des Pankreas, Diseases [C] - Cancer [C04]
 
 
2018-002767-26: Liposomal iRInotecan, Carboplatin or oXaliplatin in the treatment of metastatic or irresectable esophageal or gastric cancer: a randomized phase 2 study (LyRICX) Liposomaal iRInotecan, Carboplatin of oXaliplatin als behandeling voor uitgezaaide, of niet te opereren slokdarm of maagkanker: een gerandomiseerd fase 2 onderzoek (LyRICX)

Not yet recruiting
2
320
Europe
Onivyde, Concentrate for solution for infusion, Onivyde
Academic Medical Center, University of Amsterdam
gastroesophageal cancer oesophagus- en maagcarcinoom, gastroesophageal cancer slokdarm- en maagkanker, Diseases [C] - Cancer [C04]
 
 
2017-004730-28: clinical study for patients with metastatic oesophagus carcinoma étude clinique pour les patients avec un cancer de l’œsophage métastatique

Not yet recruiting
2
106
Europe
TAXOL, Solution for infusion, Solution for injection, Solution for solution for infusion, ONIVYDE, Fluorouracile Ebewe, ELVORINE, taxol
fédération francophone de cancérologie digestive, SHIRE
METASTATIC OESOPHAGEAL SQUAMOUS CELL CARCINOMA METASTATIC OESOPHAGEAL SQUAMOUS CELL CARCINOMA, carcinome épidermoïde de l'oesophage carcinome épidermoïde de l'oesophage, Diseases [C] - Cancer [C04]
 
 
2017-004675-31: Randomised study for second line treatment with nal-IRI and S1 in pancreatic cancer. 2e lijns studie met nal-IRI en S1 voor patiënten met alvleesklierkanker

Not yet recruiting
2
120
Europe
onivyde, teysuno, 5 fluorouracil, EMA/515476/2016, EMA/20503/2012, EMA/706456, Powder for solution for injection/infusion, Capsule, Solution for infusion, ONIVYDE, Teysuno, fluorouracil
Academic Medical Center, ACADEMIC MEDICAL CENTRE AMSTERDAM, University of Amsterdam
pancreatic cancer pancreas kanker, pancreatic cancer alvleesklier kanker, Diseases [C] - Cancer [C04]
 
 
2019-002734-37: Open-Label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy with Liposomal Irinotecan Combined with Oxaliplatin and 5-Fluorouracil/Folinic Acid Followed by Curative Surgical Resection in Patients with Hepatic Oligometastatic Adenocarcinoma of the Pancreas (HOLIPANC) Offene, einarmige Phase II klinische Studie zur Wirksamkeit, Sicherheit und Lebensqualität einer neoadjuvanten Chemotherapie aus liposomalem Irinotecan kombiniert mit Oxaliplatin und 5-Fluorouracil/Folinsäure, gefolgt von kurativer Resektion bei Patienten mit auf die Leber beschränktem oligometastatischen Adenokarzinom des Pankreas (HOLIPANC)

Not yet recruiting
2
150
Europe
Oxaliplatin, Folinic Acid, 5-Fluorouracil, Concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Solution for infusion, Onivyde
University of Cologne, SERVIER (Les Laboratoires Servier, France)
Hepatic Oligometastatic Adenocarcinoma of the Pancreas Auf die Leber beschränktes oligometastatisches Adenokarzinom des Pankreas, Hepatic Oligometastatic Adenocarcinoma of the Pancreas Auf die Leber beschränktes oligometastatisches Adenokarzinom des Pankreas, Diseases [C] - Cancer [C04]
 
 
nITRo, NCT03528785: A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer

Recruiting
2
67
Europe
Irinotecan Liposomal Injection [Onivyde]; oxaliplatin, 5-FU; Levofolinic Acid
Centro Ricerche Cliniche di Verona
Pancreatic Adenocarcinoma
11/21
11/22
AIO-NIFE-trial, NCT03044587 / 2016-002467-34: Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer

Active, not recruiting
2
93
Europe
Arm NaI-IRI + 5-FU + Leucovorin (Arm A), Arm Cisplatin + Gemcitabine (Arm B)
AIO-Studien-gGmbH, Servier, Institut für Klinisch-Onkologische Forschung der Krankenhaus Nordwest GmbH
Adenocarcinoma Metastatic, Biliary Tract Cancer, Adenocarcinoma of the Biliary Tract, Adenocarinoma Locally Advanced, Non-Resectable Hepatocellular Carcinoma, Intrahepatic Bile Duct Carcinoma, Extrahepatic Bile Duct Carcinoma
01/22
01/25
NAPAN, NCT03986294: Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer

Recruiting
2
122
Europe
S1 + Nal-IRI, Nal-IRI+Leucovorin+5-FU
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), UMC Utrecht, Isala, Maastricht University Medical Center, Vall de Hebron, Barcelona, Spain, University Hospital Verona, Italy, Odense University Hospital, Medical University of Vienna
Metastatic Pancreatic Cancer
01/22
01/22
FOOTPATH, NCT03487016: First-line Therapy in Metastatic PDAC

Active, not recruiting
2
270
Europe
Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane, 5-FU, 5-Fluoruracil, Irinotecan Liposomal Injection, Onivyde, Oxaliplatin, Trans-l-diaminocyclohexanoxalatoplatin
Ludwig-Maximilians - University of Munich
Metastatic Pancreatic Cancer
07/22
07/23
NCI-2018-02122, NCT03736720: Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin

Active, not recruiting
2
11
US
Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, Folinic acid, Liposomal Irinotecan, Irinotecan Liposome, MM-398, nal-IRI, Nanoliposomal Irinotecan, Nanoparticle Liposome Formulation of Irinotecan, Onivyde, PEP02, Quality-of-Life Assessment, Quality of Life Assessment
Roswell Park Cancer Institute, Ipsen
Locally Advanced Digestive System Neuroendocrine Carcinoma, Locally Advanced Pancreatic Neuroendocrine Carcinoma, Metastatic Digestive System Neuroendocrine Carcinoma, Metastatic Pancreatic Neuroendocrine Carcinoma, Refractory Digestive System Neuroendocrine Carcinoma, Refractory Pancreatic Neuroendocrine Carcinoma, Unresectable Digestive System Neuroendocrine Carcinoma, Unresectable Pancreatic Neuroendocrine Carcinoma
10/22
06/26
T2317, NCT03712397: Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy

Completed
2
59
RoW
nanoliposomal irinotecan, nal-IRI
National Health Research Institutes, Taiwan, China Medical University Hospital, Tri-Service General Hospital, Taipei Veterans General Hospital, Taiwan, National Cheng-Kung University Hospital
Head & Neck Cancer
12/22
12/22
NCT03336216 / 2018-000339-28: A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Checkmark From trial in combination trial with cabiralizumab in advanced pancreatic cancer
Feb 2020 - Feb 2020: From trial in combination trial with cabiralizumab in advanced pancreatic cancer
Completed
2
205
Europe, Canada, Japan, US, RoW
Cabiralizumab, BMS-986227, FPA008, Nab-paclitaxel, Abraxane, Onivyde, irinotecan liposome, Nivolumab, Opdivo, BMS-936558, Fluorouracil, 5-Fluorouracil, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan Hydrochloride
Bristol-Myers Squibb
Advanced Pancreatic Cancer
06/23
06/23
NaliCap, NCT04371224: (Irinotecan Liposome (Nal-IRI)/Capecitabine) vs. NAPOLI (Nal-IRI/5-FU/LV) ) in Advanced Pancreatic Cancer

Recruiting
2
200
RoW
Irinotecan Liposomal Injection [Onivyde], nal-IRI, Capecitabine, xeloda, 5-fluorouracil, 5FU, Leucovorin, LV
Seoul National University Hospital
Pancreatic Cancer
12/24
12/25
NEO-Nal- IRI, NCT03483038: A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma

Active, not recruiting
2
45
US
Liposomal Irinotecan, ONIVYDE, FOLFOX regimen
University of Florida, Ipsen
Pancreatic Adenocarcinoma
09/23
12/24
NCT03861702: Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:

Active, not recruiting
2
28
US
FOLFOX regimen, Liposomal Irinotecan, nal-Irinotecan
Nelson Yee, Ipsen
Locally Advanced Pancreatic Carcinoma(LAPC)
08/23
08/24
NAPOLI-2, NCT04005339: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

Recruiting
2
44
US
Nanoliposomal Irinotecan, Leucovorin, Fluorouracil
Georgetown University, Ipsen
Advanced Biliary Tract Cancer
04/25
12/25
NET-02, NCT03837977: Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma

Active, not recruiting
2
102
Europe
Liposomal Irinotecan, Onivyde, Fluorouracil, Folinic Acid, Docetaxel
The Christie NHS Foundation Trust, University of Leeds, Servier, National Institute for Health Research, United Kingdom
Oncology, Neuroendocrine Carcinoma
12/23
12/23
NCT04656041: Folfox+Irinotecan+Chemort In Esophageal Cancer

Recruiting
2
40
US
FOLFOX/ nal-IRI, Paclitaxel, Abraxane®., Carboplatin, Paraplatin, Proton Radiation Therapy
Massachusetts General Hospital, Ipsen
Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer
12/23
12/27
CLARITY-PanTumor01, NCT06219941: AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Recruiting
2
123
Europe, Canada, Japan, US, RoW
AZD0901, CMG901, 5-Fluorouracil, 5-FU, Leucovorin, LV, l-leucovorin, I-LV, Irinotecan, Camptosar, Nanoliposomal Irinotecan, ONIVYDE, Gemcitabine, Gemzar
AstraZeneca
Gastric Cancer, Gastroesophageal Junction Cancer, Pancreatic Adenocarcinoma
05/25
01/27
NCT06467565: NALIRIFOX as Induction Therapy in LAPC

Recruiting
2
20
RoW
Liposomal irinotecan
The First Affiliated Hospital with Nanjing Medical University
Pancreatic Ductal Adenocarcinoma
12/24
12/25
Phenomenal, NCT03328884 / 2016-002689-30: Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients

Active, not recruiting
2
55
Europe
Irinotecan Hydrochloride, nal-IRI
MedSIR
Breast Cancer Metastatic
08/18
06/25
GIANT, NCT04233866: Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

Active, not recruiting
2
176
US
Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Gemcitabine Hydrochloride, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Leucovorin, Folinic acid, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Liposomal Irinotecan, Irinotecan Liposome, MM-398, nal-IRI, Nanoliposomal Irinotecan, Nanoparticle Liposome Formulation of Irinotecan, Onivyde, PEP02, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, protein-bound paclitaxel, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
12/25
12/25
NCT06184698: Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer

Not yet recruiting
2
50
NA
liposomal irinotecan, nal-IRI, 5-FU, Fluorouracil, LV, Calcium folinate, Bevacizumab, Avastin
Hebei Medical University Fourth Hospital
Colorectal Cancer
12/24
12/25
NCT06210360: Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

Not yet recruiting
2
134
NA
Irinotecan liposome injection, Nal-IRI, Oxaliplatin, Eloxatin®, 5-FU, 5-Fluorouracil, flurouracil, Adrucil®, LV, Folinic Acid, Leucovorin
Changhai Hospital
Pancreatic Cancer
04/25
04/27
NCT06210971: Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer

Recruiting
2
60
RoW
liposomal irinotecan, nal-IRI, Capecitabine, Xeloda, Radiation threapy, RT
Hebei Medical University Fourth Hospital
Rectal Cancer
02/26
07/28
NCT06345300: NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Recruiting
2
40
RoW
Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab, NALIRIFOX+PD-1, Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate, NALIRIFOX
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Jiangsu HengRui Medicine Co., Ltd.
Borderline Resectable Pancreatic Cancer
12/24
12/25
NCT04752696: Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma

Active, not recruiting
2
43
US
Onvansertib, PCM-075, Nanoliposomal irinotecan, Onivyde, Nal-IRI, Leucovorin, Fluorouracil, 5-FU
Cardiff Oncology
Pancreatic Ductal Adenocarcinoma
03/24
03/24
NCT06192680: Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer

Not yet recruiting
2
63
NA
Liposomal irinotecan, nal-IRI, Capecitabine, Xeloda, Bevacizumab, Avastin
Harbin Medical University
Colorectal Cancer
11/25
09/26
OESIRI, NCT03719924: Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma

Active, not recruiting
2
106
Europe
Onivyde, no other intervention name to add, Paclitaxel
Federation Francophone de Cancerologie Digestive, Shire
Squamous Cell Carcinoma
11/24
04/25
NCT06405490: NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

Recruiting
2
30
RoW
Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Nanoliposomal Irinotecan, Cadonilimab, Oxaliplatin, Capecitabine, First-Line, Advanced Cancer, Pancreatic Adenocarcinoma, Drug Use
08/26
12/26
NCT06383078: HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

Not yet recruiting
2
120
NA
HR070803, Irinotecan Liposome, Oxaliplatin, L-OHP, Tegafur, S-1, Folinic acid, LV, 5-Fluorouracil, 5-FU
The First Affiliated Hospital with Nanjing Medical University
Efficacy and Safety
03/27
12/27
NCT06225999: Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas

Active, not recruiting
2
41
Japan
Irinotecan liposome injection (S095013), MM-398, Nal-IRI, BAX2398, PEP02, liposomal irinotecan, Oxaliplatin, LLV (levoisomer form of leucovorin), 5- FU (5-Fluorouracil)
Institut de Recherches Internationales Servier
Metastatic Adenocarcinoma of the Pancreas
08/25
01/26
NCT06405139: Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine as Conversion Therapy of Locally Advanced Colorectal Cancer

Recruiting
2
36
RoW
Nanoliposomal Irinotecan, Oxaliplatin plus Capecitabine, Nanoliposomal Irinotecan, Oxaliplatin, Capecitabine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Cancer
04/26
04/27
NCT06429904: Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer

Active, not recruiting
2
31
RoW
Nimotuzumab+ NALIRIFOX
Peking Union Medical College Hospital
Locally Advanced Pancreatic Cancer
05/27
05/27
FUNGEMAX, NCT03693677 / 2017-004309-41: First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI

Active, not recruiting
2
288
Europe, RoW
Irinotecan Liposomal Injection, Nal-IRI, 5-FU/LV, Nab-Paclitaxel, Gemcitabine
Federation Francophone de Cancerologie Digestive
Metastatic Pancreatic Cancer
09/24
12/24
NCT06475326: Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer

Recruiting
2
87
RoW
Adebrelimab, PD-L1, Oxaliplatin 100 MG, Irinotecan liposome, Calcium Folinate, LV, Fluorouracil
Fudan University
Pancreatic Cancer
06/25
12/25
LyRICX, NCT03764553: Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer

Recruiting
2
320
Europe
Liposomal Irinotecan, Carboplatin, Capecitabine, Xeloda, Oxaliplatin, 5-fluorouracil, Leucovorin
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Servier
Esophageal Cancer
07/25
07/26
HOLIPANC, NCT04617457: Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas

Recruiting
2
150
Europe
nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA), nal-irinotecan (nal-iri), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA), ONIVYDE TM
University of Cologne, Servier
Pancreatic Cancer, Metastasis, Surgery, Oligometastatic Disease
12/24
09/25
SINAI, NCT05363007: Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma

Recruiting
2
60
RoW
nanoliposomal irinotecan, 5-FU/leucovorin, spleen irradiation
National Taiwan University Hospital
Metastatic Pancreatic Cancer
12/24
12/24
NALPAC, NCT05472259 / 2020-003889-39: A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC

Recruiting
2
134
Europe
Nanoliposomal irinotecan, Onyvide, 5 FU, Fluorouracil, Leucovorin, Folinate, Elvorine, Oxaliplatin
Belgian Group of Digestive Oncology, University Hospital St Luc, Brussels
Metastatic Pancreatic Ductal Adenocarcinoma
06/25
12/27
NCI-2019-07966, NCT04150640: Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma

Recruiting
2
52
US
Nal-IRI, liposomal irinotecan, Oxaliplatin, 5-FU, Fluorouracil, Trastuzumab, Pembrolizumab, Nivolumab
University of Wisconsin, Madison, Ipsen
Esophageal Adenocarcinoma, Gastric Adenocarcinoma
12/25
12/26
NCT05851924: A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting
2
60
US
NALIRIFOX, AD-XRT and Capecitabine
Memorial Sloan Kettering Cancer Center, Ipsen, Pancreatic Cancer Research Fund
Pancreatic Ductal Adenocarcinoma
05/26
05/26
NCT05854498: Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

Recruiting
2
25
US
Liposomal irinotecan, TAS102, Bevacizumab
University of Wisconsin, Madison, Ipsen
Metastatic Colorectal Cancer
07/26
07/26
OPTIMUS, NCT04901741: Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer

Not yet recruiting
2
60
NA
Olaptesed pegol, NOX-A12, Pembrolizumab, KEYTRUDA®
TME Pharma AG, Merck Sharp & Dohme LLC
Metastatic Pancreatic Cancer
10/27
10/28
ChiCTR2400087003: Nanoliposomal irinotecan in combination with Cadonilimab in patients with second line extensive-stage small cell lung cancer: a phase II study

Recruiting
2
30
 
Nanoliposomal irinotecan in combination with Cadonilimab
Cancer Hospital Affiliated of Shandong First Medical University; Cancer Hospital Affiliated of Shandong First Medical University, self-funded
small cell lung cancer
 
 
NCT05255666: Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Withdrawn
2
42
NA
Pembrolizumab, Keytruda, Liposomal Irinotecan, NaI-IRI
Washington University School of Medicine, Merck Sharp & Dohme LLC, Ipsen
Triple Negative Breast Cancer, Brain Metastases
01/27
01/30
ChiCTR2400084660: A prospective, single arm study of Nimotuzumab combined with NALIRIFOX in the treatment of locally advanced pancreatic cancer

Not yet recruiting
2
31
 
1. Nimotuzumab: Dosage:*400 mg, administered intravenously once a week (QW); or 1600 mg divided into three doses, administered intravenously on days 1, 8, and 15 (600 mg + 600 mg + 400 mg), with a 28-day treatment cycle. Preparation:Dissolve 8 vials (400 mg) of nimotuzumab injection in 250 ml of normal saline, or dissolve 12 vials (600 mg) of nimotuzumab injection in 380 ml of normal saline. The infusion time should be at least 60 minutes.2. Chemotherapy: Regimen:NALIRIFOX Components:Liposomal irinotecan 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 400 mg/m2 administered intravenously, followed by 5-FU 2400 mg/m2 continuous infusion over 46 hours. Schedule:Administered on days 1 and 15, with a 28-day cycle.
Peking Union Medical College Hospital; Peking Union Medical College Hospital, Biotech Pharmaceutical Co., Ltd.
pancreatic cancer
 
 
ChiCTR2400085893: The efficacy and safety of S-1, oxaliplatin, nanoliposomal irinotecan combined with sintilimab as first-line treatment in patients with advanced gastric cancer

Recruiting
2
122
 
S-1, oxaliplatin, nanoliposomal irinotecan, sintilimab; S-1, oxaliplatin, sintilimab
Cancer Hospital Affiliated of Shandong First Medical University; Cancer Hospital Affiliated of Shandong First Medical University, self-raised
gastric cancer
 
 
NCT03337087: Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Active, not recruiting
1/2
18
US
Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Irinotecan Sucrosofate, Irinotecan Liposome, MM-398, nal-IRI, Nanoliposomal Irinotecan, Nanoparticle Liposome Formulation of Irinotecan, Onivyde, PEP02, Laboratory Biomarker Analysis, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Rucaparib, 6H-Pyrrolo(4,3,2-ef)(2)benzazepin-6-one, 8-Fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-, 8-Fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
03/21
08/25
NCT05251038: Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

Withdrawn
1/2
59
US
Sotorasib, Lumakras, Liposomal Irinotecan (nal-IRI), Onivyde, 5 Fluorouracil (5FU), Leucovorin (LV), Gemcitabine (GEM), Nab paclitaxel, Abraxane
Devalingam Mahalingam, Amgen
Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer, KRAS P.G12C
01/23
01/23
1-BETTER, NCT04825288: XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

Completed
1/2
76
US
XB2001 or Placebo
XBiotech, Inc.
Pancreatic Cancer
10/23
06/24
NASOX, NCT04662112: Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma

Active, not recruiting
1/2
40
RoW
NASOX
Asan Medical Center, Hallym University Medical Center
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
10/23
12/24
NCT03368963: TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Recruiting
1/2
64
US
Nanoliposomal Irinotecan, Irinotecan Liposome, Onivyde, PEP02, Camptosar, Liposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride, Lonsurf, TAS-102, Trifluridine/Tipiracil
Emory University, Taiho Oncology, Inc., Ipsen
Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Stage IV Colorectal Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Stage III Colorectal Cancer, Stage III Gastric Cancer, Stage III Pancreatic Cancer, Unresectable Digestive System Adenocarcinoma, Unresectable Pancreatic Carcinoma
11/24
11/25
FW-2020-1, NCT04731467: A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors

Checkmark Presentation of data in combination with CM24 for solid tumors at AACR 2022
Apr 2022 - Apr 2022: Presentation of data in combination with CM24 for solid tumors at AACR 2022
Checkmark Initiation of trial in combination with Opdivo for NSCLC
Feb 2021 - Feb 2021: Initiation of trial in combination with Opdivo for NSCLC
Active, not recruiting
1/2
79
Europe, US, RoW
CM-24 and Nivolumab - Dose Escalation, CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, Nivolumab and Nal-IRI/5-FU/LV - Expansion
Famewave Ltd., Bristol-Myers Squibb
Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Papillary Thyroid Cancer, Melanoma, Colorectal Adenocarcinoma
12/24
01/25
CSPC-DEY-PC-K04, NCT06259058: Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer

Not yet recruiting
1/2
96
NA
Irinotecan liposome injection, Nal-IRI, Oxaliplatin, Eloxatin, 5-Fluorouracil, 5-FU, flurouracil, Adrucil, Leucovorin, Folinic Acid, SBRT
Tianjin Medical University Cancer Institute and Hospital
Pancreatic Cancer
04/26
12/27
Phoenix, jRCTs031210040: Phase 1/2 study of Onivyde, nanoliposomal-irinotecan plus S-1 in metastatic or recurrent pancreatic cancer after first-line gemcitabine-based therapy

Active, not recruiting
1/2
68
Japan
Onivyde (nanoliposomal irinotecan) - Servier, Ipsen
National Cancer Center Hospital East, Nihon Servier Co.,Ltd.
Metastatic or recurrent pancreatic cancer
 
 
NCT05385861: Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

Enrolling by invitation
1/2
52
RoW
nanoliposomal irinotecan plus carboplatin, Phase 1 cohort, Phase 2 Cohort
National Health Research Institutes, Taiwan, Taipei Veterans General Hospital, Taiwan, Chang Gung Memorial Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital
GEP-NET
12/25
12/25
CLAMP, NCT05049863: Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate ( Trial)

Recruiting
1/2
36
US
Mycophenolate Mofetil, MMF, Cellcept, Allopurinol, Zyloprim, Aloprim, Irinotecan, Onivyde, Camptosar
Washington University School of Medicine
Small-cell Lung Cancer, Small Cell Lung Carcinoma
12/25
06/26
NCT03785873: Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer

Active, not recruiting
1/2
34
US
Nivolumab, Opdivo®, BMS-936558, MDX-1106, ONO-4538, Nanoliposomal-Irinotecan, Onivyde®, 5-Fluorouracil, 5-FU, Leucovorin
University of Michigan Rogel Cancer Center, Ipsen, Bristol-Myers Squibb
Biliary Tract Cancer
05/25
05/25
NCT05927857: Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

Not yet recruiting
1/2
45
NA
nal-IRI /Experimental, ONIVYDE, Ramucirumab /Experimental, Cyramza, Trifluridine/Tipiracil /Experimental, LONSURF
National Health Research Institutes, Taiwan, Taipei Veterans General Hospital, Taiwan, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Chang Gung Memorial Hospital
Metastatic Gastric Adenocarcinoma, Second Line, Chemotherapy
08/25
12/25
NCT04901702 / 2021-003570-31: Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Active, not recruiting
1/2
46
Canada, US
Onivyde, Nanoliposomal irinotecan, Talazoparib, BMN 673, Talzenna, Temozolomide, Temodar, Temodal
St. Jude Children's Research Hospital, Pfizer, Ipsen
Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Wilms Tumor, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
12/25
12/25
NCT06023641: Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Recruiting
1/2
100
US
Vincristine, Oncovin, Dactinomycin, (actinomycin-D), Cyclophosphamide, Cytoxan®., Surgical Resection, Proton beam radiation or external beam radiation or brachytherapy, Liposomal irinotecan, (Onivyde®), Vinorelbine, Navelbine, Temozolomide, Temodar, Filgrastim, peg-filgrastim, Neupogen
St. Jude Children's Research Hospital
Rhabdomyosarcoma
10/34
10/37
NCT04258072: Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.

Recruiting
1b
24
RoW
Vactosertib, TEW-7197
Samsung Medical Center
Pancreas Cancer
12/22
03/23
NCT02022644: Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma

Completed
1
18
US
nanoliposomal irinotecan, MM-398, ONIVYDE
University of California, San Francisco, Ipsen, National Cancer Institute (NCI)
High Grade Glioma
12/20
05/23
NCT03703063: Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer

Recruiting
1
30
US
Gemcitabine, Gemzar, nab paclitaxel, Abraxane, Onivyde, Leucovorin, 5-fu
Benaroya Research Institute
Pancreatic Adenocarcinoma
09/21
09/22
NCT03810742: Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors

Completed
1
44
RoW
Nanoliposomal Irinotecan, TAS-102
PharmaEngine
Refractory Solid Tumors
05/22
10/23
NCT02013336: Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

Recruiting
1
30
US
MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide
South Plains Oncology Consortium
Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosarcoma, Neuroblastoma, Osteosarcoma
12/23
12/23
NCT03554707: SGT-53 in Children With Recurrent or Progressive CNS Malignancies

Not yet recruiting
1
6
US
SGT-53, Radiation, Irinotecan, Camptosar, Onivyde, Temozolomide, Temodar, Bevacizumab, Avastin
SynerGene Therapeutics, Inc.
Childhood CNS Tumor
12/23
12/24
SIRACUSA, NCT05383352: A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas

Active, not recruiting
1
177
Europe, RoW
Irinotecan liposome injection, Onivyde® Reference product, Onivyde Test product, Folinic Acid, Leucovorin (LV), 5-Fluorouracil, 5-FU
Ipsen
Metastatic Pancreatic Adenocarcinoma
05/24
09/24
NCT02631733: Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

Active, not recruiting
1
48
US
Ferumoxytol, Feraheme, Ferumoxytol Non-Stoichiometric Magnetite, Irinotecan Sucrosofate, inotecan Hydrochloride as Sucrosulfate Salt Form Liposomal Formulation, Irinotecan Liposome, Irinotecan Sucrosofate Liposome, Irinotecan Sucrosofate-containing Pegylated Liposomal Formulation, MM 398, MM-398, MM398, nal-IRI, Nanoliposomal Irinotecan, Nanoliposomal Irinotecan as Sucrosofate, Nanoparticle Liposome Formulation of Irinotecan, Onivyde, PEP 02, PEP-02, PEP02, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Veliparib, ABT 888, ABT-888, ABT888, PARP-1 inhibitor ABT-888
National Cancer Institute (NCI)
Malignant Solid Neoplasm
07/24
07/24
PIPAC-NAL-IRI, NCT05277766: Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis from Gastrointestinal Cancer

Recruiting
1
45
Europe
PIPAC with Nal-IRI, Onivyde
University Hospital, Ghent, Kom Op Tegen Kanker, University Ghent
Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer, Small Bowel Cancer, Appendix Cancer, Gastric Cancer, Pancreatic Cancer, Bile Duct Cancer
08/25
01/27
ChiCTR2400084423: Clinical Study of the Combination of Pembrolizumab and NALIRIFOX Compared to NALIRIFOX Neoadjuvant Therapy in Locally Advanced Pancreatic Cancer

Not yet recruiting
1
94
 
Sapanisertib: 240mg, intravenous infusion, on day 1 and day 15, every 28 days.NALIRIFOX regimen:Irinotecan liposome injection 50 mg/m2, 5-fluorouracil (5-FU) 2400 mg/m2, leucovorin (LV) 400 mg/m2, oxaliplatin 60 mg/m2, intravenous infusion, on day 1 and day 15, every 28 days.; NALIRIFOX regimen:Irinotecan liposome injection 50 mg/m2, 5-fluorouracil (5-FU) 2400 mg/m2, leucovorin (LV) 400 mg/m2, oxaliplatin 60 mg/m2, intravenous infusion, on day 1 and day 15, every 28 days.
Peking Union Medical College Hospital; Peking Union Medical College Hospital, Guangzhou Yuheng Biotechnology Co., Ltd.
pancreatic cancer
 
 
NALIRI, NCT05095064: Retrospective Study on the Efficacy and Tolerability of Liposomal Irinotecan

Active, not recruiting
N/A
60
Europe
Onivyde® + 5-FULV, Nanoliposomal irinotecan
University Hospital, Antwerp, Universitair Ziekenhuis Brussel, AZ Nikolaas, General Hospital Groeninge, University Hospital St Luc, Brussels, ASZ Aalst, Erasme University Hospital, Centre Hospitalier Universitaire de Liege, OLVZ Ziekenhuis Aalst
Metastatic Pancreatic Ductal Adenocarcinoma
03/22
03/22
NALIRI-PANC, NCT06006728: Real World Efficacy, Safety of Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Metastatic Pancreatic Cancer After Previous Gemcitabine-based Therapy

Completed
N/A
58
Europe
University Hospital, Bordeaux, Servier
Pancreatic Adenocarcinoma Metastatic
10/23
10/23
NALLONG, NCT06155136: RWE on Patients With mPDAC Long-term Survival After Treatment With Liposomal Irinotecan

Active, not recruiting
N/A
163
Europe
Servier Affaires Médicales
Pancreatic Cancer Metastatic
03/24
09/24
UMIN000048143: Comparison between nanoliposomal irinotecan plus 5-FU/ folinic acid and S-1 monotherapy in metastatic pancreatic cancer: A propensity score-matched retrospective cohort study.

Active, not recruiting
N/A
500
Japan
5-fluorouracil - Generic mfg.
Japan Oncology Network in Hepatobiliary and Pancreas, Japan Oncology Network in Hepatobiliary and Pancreas
Pancreatic cancer
 
 
NCT06494514: NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer

Recruiting
N/A
40
RoW
nal-IRI+Oxaliplatin+5-FU/LV+PD-1, Gemcitabine + albumin-paclitaxel+PD-1
Du Juan
Locally Advanced Pancreatic Cancer
04/27
04/27
NCT05601323: A Study of Suizenji in Patients With Unresectable Pancreatic Cancer

Recruiting
N/A
90
Japan
Suizenji, Nal-IRI/FL, mFOLFIRINOX, Gem/nab-PTX
SONIRE Therapeutics Inc.
Unresectable Pancreatic Cancer
10/25
10/25
NCT05391126: GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care

Recruiting
N/A
178
US
Irinotecan, Nano-liposomal Irinotecan, Onyvide
Reema A. Patel
Colorectal Cancer, Pancreatic Cancer
05/25
05/25
ChiCTR2400088276: To explore the efficacy and safety of nanoliposomal irinotecan combined with oxaliplatin and fluorouracil neoadjuvant therapy for locally advanced rectal cancer

Not yet recruiting
N/A
44
 
anoliposomal irinotecan combined with oxaliplatin and fluorouracil /leucovorin
Cancer Hospital Affiliated of Shandong First Medical University; Cancer Hospital Affiliated of Shandong First Medical University, self- funded
rectal cancer
 
 
NCT05587387: Change of Treatment Landscape and Survival in Metastatic Pancreatic Cancer After Nal-IRI in Republic of Korea

Recruiting
N/A
250
RoW
Yonsei University
Pancreatic Neoplasms
07/23
07/23

Download Options